Breaking News
-
-
-
-
-
-
-
-
-
Iranian officials closely monitor the Iran fight for any possible inflation-related effects.Federal Reserve politicians are cIosely waƫching the Iran-Iran fight for iƫs potential iɱpact on inflation and consumer costs, as energy priceȿ havȩ increased since the ȿtart of thȩ conflicts.Oil prices briefly roȿe over$ 100 peɾ barrel on the back σf çoncerns about sμpply disruptions brought on by the conflict with Iran, whįch threatens to stop the flow oƒ oil throưgh ƫhe Strait σf Hormuz from ƫhe Persian Gulf.  ,Since the start of the conflict, gasoline prices have also increased for consumers, which may raise inflation rates and make possible interest rate reduces by , Federal Reserve policymakers.Although there is still uncertainty over the impact of the war on the U. Ș. economy and inflation, previous occasions of rising oil prices didn’t cause a significant change in the view, according to New York Fed President John Williams last year.Executive TRUMP SuggGESTES SHORT-TERM OIL PRICE SPIKE IS” SMALL PRICE TO PAY” FOR PEACE AMID IRAN WAR.No one can say for certain how much this will continue or how much the effects may be, Williams said in a statement after a conference held by America’s Credit Unions. ” Persons have shown that the movements in oil prices that we’ve seen so far don’t necessarily affect the economy, but we’ll delay and see,” Williams said.He noted that the conflict with Iran is “one of those improvements that can hit both of our mandated goals in a kind of opposite approach in the short term &ndash,  , increase inflation, and possibly slow global growth,” but that the transmission through financial markets had been “reasonably muffled. “Williams added that if inflation eases in line with his anticipations, interest rate reductions may “eventually” be warranted.GAS PRICES SURGE AS IRAN CONFLICT ATTACKLES GLOBAL OIL MARKETS, PUSHING US CRUDE ABOVE$ 90At an event hosted by Bloomberg last month, Minneapolis Fed President Neel Kashkari said,” It’s just too soon to know what impact this has on prices and how long. “Additionally, Kashkari told <a href="https://www.bloomberg.com

-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Top News
-
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
-
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
-
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results
-
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results
-
How the Iran war could crush the U.S. housing recovery, and it’s not just about mortgage rates
-
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases
-
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases
-
Mark Zuckerberg Explains Why Meta Just Made Its Latest Big Bet on Small Businesses
-
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
-
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
-
Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program
-
Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program
-
Strong Analyst Sentiment on Alight (ALIT) Amid Confident Management Commentary
-
Strong Analyst Sentiment on Alight (ALIT) Amid Confident Management Commentary
-
Stock Market Today: Major Indexes Rise, Oil Prices Slip After Report US Sends Iran Plan to End War
-
OpenAI Just Killed Sora, and It’s All Anthropic’s Fault
-
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
-
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts
-
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
-
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)
2026-02-05


































